Eluxadoline has mixed opioid receptor activity and is indicated for treatment of IBS-D; however, because of the risk of pancreatitis, it cannot be used in patients who have had a cholecystectomy, have sphincter of Oddi dysfunction, have liver disease, or drink more than 3 alcoholic drinks a day.